Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries
- PMID: 23613740
- PMCID: PMC3629254
- DOI: 10.1371/journal.pone.0060732
Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries
Abstract
The introduction of mass vaccination against Varicella-Zoster-Virus (VZV) is being delayed in many European countries because of, among other factors, the possibility of a large increase in Herpes Zoster (HZ) incidence in the first decades after the initiation of vaccination, due to the expected decline of the boosting of Cell Mediated Immunity caused by the reduced varicella circulation. A multi-country model of VZV transmission and reactivation, is used to evaluate the possible impact of varicella vaccination on HZ epidemiology in Italy, Finland and the UK. Despite the large uncertainty surrounding HZ and vaccine-related parameters, surprisingly robust medium-term predictions are provided, indicating that an increase in HZ incidence is likely to occur in countries where the incidence rate is lower in absence of immunization, possibly due to a higher force of boosting (e.g. Finland), whereas increases in HZ incidence might be minor where the force of boosting is milder (e.g. the UK). Moreover, a convergence of HZ post vaccination incidence levels in the examined countries is predicted despite different initial degrees of success of immunization policies. Unlike previous model-based evaluations, our investigation shows that after varicella immunization an increase of HZ incidence is not a certain fact, rather depends on the presence or absence of factors promoting a strong boosting intensity and which might or not be heavily affected by changes in varicella circulation due to mass immunization. These findings might explain the opposed empirical evidences observed about the increases of HZ in sites where mass varicella vaccination is ongoing.
Conflict of interest statement
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3629254/bin/pone.0060732.g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3629254/bin/pone.0060732.g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3629254/bin/pone.0060732.g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3629254/bin/pone.0060732.g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3629254/bin/pone.0060732.g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3629254/bin/pone.0060732.g006.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3629254/bin/pone.0060732.g007.gif)
Similar articles
-
The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting.BMC Infect Dis. 2019 Feb 6;19(1):126. doi: 10.1186/s12879-019-3759-z. BMC Infect Dis. 2019. PMID: 30727971 Free PMC article.
-
Understanding the role of exogenous boosting in modeling varicella vaccination.Expert Rev Vaccines. 2018 Nov;17(11):1021-1035. doi: 10.1080/14760584.2018.1538801. Epub 2018 Nov 5. Expert Rev Vaccines. 2018. PMID: 30354696 Review.
-
Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.Vaccine. 2018 Feb 14;36(8):1116-1125. doi: 10.1016/j.vaccine.2018.01.038. Epub 2018 Jan 20. Vaccine. 2018. PMID: 29366704
-
Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.EBioMedicine. 2015 Aug 8;2(10):1494-9. doi: 10.1016/j.ebiom.2015.08.017. eCollection 2015 Oct. EBioMedicine. 2015. PMID: 26629544 Free PMC article.
-
The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review.J Infect Dis. 2008 Mar 1;197 Suppl 2:S224-7. doi: 10.1086/522162. J Infect Dis. 2008. PMID: 18419401 Review.
Cited by
-
Impact assessment of immunization and the COVID-19 pandemic on varicella across Europe using digital epidemiology methods: A descriptive study.PLoS One. 2023 Apr 12;18(4):e0283465. doi: 10.1371/journal.pone.0283465. eCollection 2023. PLoS One. 2023. PMID: 37043422 Free PMC article.
-
Universal varicella vaccination in Denmark: Modeling public health impact, age-shift, and cost-effectiveness.PLOS Glob Public Health. 2023 Apr 5;3(4):e0001743. doi: 10.1371/journal.pgph.0001743. eCollection 2023. PLOS Glob Public Health. 2023. PMID: 37018165 Free PMC article.
-
The health and economic impact of switching vaccines in universal varicella vaccination programs using a dynamic transmission model: An Israel case study.Hum Vaccin Immunother. 2022 Nov 30;18(6):2124784. doi: 10.1080/21645515.2022.2124784. Epub 2022 Oct 31. Hum Vaccin Immunother. 2022. PMID: 36315970 Free PMC article.
-
Modeling the Impact of Exogenous Boosting and Universal Varicella Vaccination on the Clinical and Economic Burden of Varicella and Herpes Zoster in a Dynamic Population for England and Wales.Vaccines (Basel). 2022 Aug 28;10(9):1416. doi: 10.3390/vaccines10091416. Vaccines (Basel). 2022. PMID: 36146493 Free PMC article.
-
Clinical and economic impact of universal varicella vaccination in Norway: A modeling study.PLoS One. 2021 Jul 8;16(7):e0254080. doi: 10.1371/journal.pone.0254080. eCollection 2021. PLoS One. 2021. PMID: 34237090 Free PMC article.
References
-
- Nardone A, de Oryb F, Carton M, Cohen D, van Damme P, et al. (2007) The comparative seroepidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 25(45): 7866–7872. - PubMed
-
- Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F (2011) Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin Infect Dis 52(3): 332–340. - PubMed
-
- Bilcke J, Ogunjimi B, Marais C, DE Smet F, Callens M, et al. (2012) The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect 140(11): 2096–2109. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical